GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inovio Pharmaceuticals Inc (NAS:INO) » Definitions » Shiller PE Ratio

Inovio Pharmaceuticals (Inovio Pharmaceuticals) Shiller PE Ratio : (As of Apr. 27, 2024)


View and export this data going back to 1998. Start your Free Trial

What is Inovio Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Inovio Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Inovio Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inovio Pharmaceuticals Shiller PE Ratio Chart

Inovio Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Inovio Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Inovio Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Inovio Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inovio Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inovio Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Inovio Pharmaceuticals's Shiller PE Ratio falls into.



Inovio Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Inovio Pharmaceuticals's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Inovio Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-1.05/129.4194*129.4194
=-1.050

Current CPI (Dec. 2023) = 129.4194.

Inovio Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -2.400 99.695 -3.116
201406 -2.280 100.560 -2.934
201409 -1.440 100.428 -1.856
201412 -1.440 99.070 -1.881
201503 -2.160 99.621 -2.806
201506 -1.080 100.684 -1.388
201509 0.840 100.392 1.083
201512 -3.120 99.792 -4.046
201603 -1.320 100.470 -1.700
201606 -3.120 101.688 -3.971
201609 -3.360 101.861 -4.269
201612 -4.320 101.863 -5.489
201703 -3.720 102.862 -4.680
201706 -1.560 103.349 -1.954
201709 -4.800 104.136 -5.965
201712 -2.880 104.011 -3.584
201803 -4.320 105.290 -5.310
201806 -0.960 106.317 -1.169
201809 -3.240 106.507 -3.937
201812 -4.200 105.998 -5.128
201903 -3.600 107.251 -4.344
201906 -3.600 108.070 -4.311
201909 -3.000 108.329 -3.584
201912 -4.560 108.420 -5.443
202003 -3.120 108.902 -3.708
202006 -9.960 108.767 -11.851
202009 1.320 109.815 1.556
202012 -1.320 109.897 -1.554
202103 -3.240 111.754 -3.752
202106 -4.680 114.631 -5.284
202109 -3.480 115.734 -3.891
202112 -6.050 117.630 -6.656
202203 -4.320 121.301 -4.609
202206 -5.520 125.017 -5.714
202209 -1.800 125.227 -1.860
202212 -2.550 125.222 -2.635
202303 -1.920 127.348 -1.951
202306 -1.560 128.729 -1.568
202309 -1.560 129.860 -1.555
202312 -1.050 129.419 -1.050

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Inovio Pharmaceuticals  (NAS:INO) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Inovio Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Inovio Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Inovio Pharmaceuticals (Inovio Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
660 West Germantown Pike, Suite 110, Plymouth Meeting, PA, USA, 19462
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Executives
Lota S. Zoth director 334 CR 692, BUFFALO GAP TX 79508
David B. Weiner director 717 BEACOM LANE, MERION STATION PA 19066-1603
Simon X Benito director 967 LAWRENCE AVE, WESTFIELD NJ 07090
Michael John Sumner officer: Chief Medical Officer 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Laurent Humeau officer: Chief Scientific Officer C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Jacqueline Elizabeth Shea officer: Chief Operating Officer C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Peter Kies officer: CFO
Roger D Dansey director 21823 30TH DRIVE SE, BOTHELL WA 98021
Jong Joseph Kim director, officer: Chief Executive Officer 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Jay Shepard director 15977 GRANDVIEW AVENUE, MONTE SERENO CA 95030
Ann Calby Miller director C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Wendy L Yarno director
Morton Collins director
George Bickerstaff director C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Niranjan Sardesai officer: Chief Operating Officer VGX PHARMACEUTICALS, INC., 450 SENTRY PARKWAY, BLUE BELL PA 19422